

A. Progression-free survival of individual trials

Study	Chemotherapy (total)	Endocrine therapy (total)	HR	95%CI
Tredan 2016	59	58	1.00	(0.70; 1.50)

Test for overall effect:  $z=0.000$  ( $p=0.998$ )



B. Progression-free survival of pooled trials (Network)

Study	Chemotherapy (total)	Endocrine therapy (total)	HR	95%CI
Network	1456	104	1.00	(0.73; 1.37)

Test for overall effect:  $z=0.000$  ( $p=1.000$ )



C. Overall survival of individual trials

Study	Chemotherapy (total)	Endocrine therapy (total)	HR	95%CI
Tredan 2016	59	58	1.15	(0.59; 2.22)

Test for overall effect:  $z=0.410$  ( $p=0.679$ )



D. Overall survival of pooled trials (Network)

Study	Chemotherapy (total)	Endocrine therapy (total)	HR	95%CI
Network	1456	104	1.02	(0.68; 1.53)

Test for overall effect:  $z=0.10$  ( $p=0.920$ )



**S4 Fig.** Pooled hazard ratios for progression-free survival and overall survival with chemotherapy versus endocrine therapy maintenance [5]. CI, confidence interval; HR, hazard ratio.